Proactive Investors - Run By Investors For Investors

Circassia Pharmaceuticals adds 'exciting, near-term' respiratory drug to portfolio

Steve Harris, chief executive of Circassia Pharmaceuticals PLC (LON:CIR), tells Proactive London's Andrew Scott they've acquired the exclusive US and Chinese commercialisation rights to AirNOvent – a treatment for persistent pulmonary hypertension (PPHN) of newborns.

PPHN occurs when the pressure in the blood vessels of a baby’s lungs remains high after birth, which can restrict the amount of oxygen flowing around the body and make the newborn unwell.

It's thought to occur in around one in 500 births.

 
View full CIR profile View Profile

Circassia Pharmaceuticals Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use